144 related articles for article (PubMed ID: 31685378)
21. Rare incidence of non-secretory myeloma with talaromycosis: a case report.
Qin H; Qiu Y; Huang Y; Pan M; Lan D; Zeng W; Zhang J
BMC Infect Dis; 2021 Sep; 21(1):964. PubMed ID: 34530743
[TBL] [Abstract][Full Text] [Related]
22. Non Secretory Multiple Myeloma With Extensive Extramedullary Plasmacytoma: A Diagnostic Dilemma.
Low SF; Mohd Tap NH; Kew TY; Ngiu CS; Sridharan R
Iran J Radiol; 2015 Jul; 12(3):e11760. PubMed ID: 26528383
[TBL] [Abstract][Full Text] [Related]
23. International prognostic index (IPI)--a critical comparison with five multiple myeloma staging systems in the group of 270 patients treated by conventional chemotherapy.
Scudla V; Zemanova M; Minarik J; Bacovsky J; Ordeltova M; Indrak K; Budikova M; Dusek L; Farbiakova V
Neoplasma; 2006; 53(4):277-84. PubMed ID: 16830053
[TBL] [Abstract][Full Text] [Related]
24. Tandem Autologous Stem Cell Transplantation Improves Outcomes in Newly Diagnosed Multiple Myeloma with Extramedullary Disease and High-Risk Cytogenetics: A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.
Gagelmann N; Eikema DJ; Koster L; Caillot D; Pioltelli P; Lleonart JB; Reményi P; Blaise D; Schaap N; Trneny M; Passweg J; Porras RP; Cahn JY; Musso M; Poiré X; Fenk R; Itälä-Remes M; Pavone V; Fouillard L; Maertens J; Bron D; Pouli A; Schroyens W; Schönland S; Garderet L; Yakoub-Agha I; Kröger N
Biol Blood Marrow Transplant; 2019 Nov; 25(11):2134-2142. PubMed ID: 31288095
[TBL] [Abstract][Full Text] [Related]
25. Novel Induction Regimens in Multiple Myeloma.
Runcie KD; Mark TM
Curr Hematol Malig Rep; 2015 Dec; 10(4):388-94. PubMed ID: 26275667
[TBL] [Abstract][Full Text] [Related]
26. Case report: amyloid tumors in a case of non-secretory multiple myeloma.
Richter S; Makovitzky J
Acta Histochem; 2006; 108(3):221-6. PubMed ID: 16714048
[TBL] [Abstract][Full Text] [Related]
27. Impact of induction treatment before autologous stem cell transplantation on long-term outcome in patients with newly diagnosed multiple myeloma.
Gassiot S; Motlló C; Llombart I; Morgades M; González Y; Garcia-Caro M; Ribera JM; Oriol A
Eur J Haematol; 2017 Jun; 98(6):569-576. PubMed ID: 28208219
[TBL] [Abstract][Full Text] [Related]
28. Diffuse pattern of bone marrow involvement on magnetic resonance imaging is associated with high risk cytogenetics and poor outcome in newly diagnosed, symptomatic patients with multiple myeloma: a single center experience on 228 patients.
Moulopoulos LA; Dimopoulos MA; Kastritis E; Christoulas D; Gkotzamanidou M; Roussou M; Koureas A; Migkou M; Gavriatopoulou M; Eleutherakis-Papaiakovou E; Gika D; Koutoulidis V; Terpos E
Am J Hematol; 2012 Sep; 87(9):861-4. PubMed ID: 22641455
[TBL] [Abstract][Full Text] [Related]
29. Clinical features and survival of 338 multiple myeloma patients treated with hematopoietic stem cell transplantation or conventional chemotherapy.
Pérez R; Durán MS; Mayans J; Soler A; Castillo I; Jurado M; Ribas P; Menchaca Echevarria MC; Hernandez MT; Lopez Garcia-Carreño MD; Echeveste Gutierrez A; Bailen Garcia A; Lopez S; Baquero J; Ramirez G
Eur J Haematol; 2016 Apr; 96(4):417-24. PubMed ID: 26190662
[TBL] [Abstract][Full Text] [Related]
30. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.
Kim HJ; Yoon SS; Lee DS; Sohn SK; Eom HS; Lee JL; Chung JS; Kim K; Suh C; Won JH; Kim JS; Park JS; Kang HJ; Seong CM; Kim CS; Lee SJ; Lee JH
Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621
[TBL] [Abstract][Full Text] [Related]
31. Clinical course and prognosis of non-secretory multiple myeloma.
Chawla SS; Kumar SK; Dispenzieri A; Greenberg AJ; Larson DR; Kyle RA; Lacy MQ; Gertz MA; Rajkumar SV
Eur J Haematol; 2015 Jul; 95(1):57-64. PubMed ID: 25382589
[TBL] [Abstract][Full Text] [Related]
32. An abnormal nonhyperdiploid karyotype is a significant adverse prognostic factor for multiple myeloma in the bortezomib era.
Tan D; Teoh G; Lau LC; Lim A; Lim TH; Yap KC; Premalatha P; Lao ZT; Wee N; Choo C; Wee HC; Su S; Lee YS; Lee LH; Hwang W; Goh YT
Am J Hematol; 2010 Oct; 85(10):752-6. PubMed ID: 20721886
[TBL] [Abstract][Full Text] [Related]
33. Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma.
Gonsalves WI; Leung N; Rajkumar SV; Dispenzieri A; Lacy MQ; Hayman SR; Buadi FK; Dingli D; Kapoor P; Go RS; Lin Y; Russell SJ; Lust JA; Zeldenrust S; Kyle RA; Gertz MA; Kumar SK
Blood Cancer J; 2015 Mar; 5(3):e296. PubMed ID: 25794132
[TBL] [Abstract][Full Text] [Related]
34. Autologous Stem Cell Transplantation in Multiple Myeloma in the Era of Novel Drug Induction: A Retrospective Single-Center Analysis.
Thoennissen GB; Görlich D; Bacher U; Aufenberg T; Hüsken AC; Hansmeier AA; Evers G; Mikesch JH; Fritz F; Bokemeyer C; Müller-Tidow C; Stelljes M; Mesters RM; Krug U; Kropff MH; Thoennissen NH; Berdel WE
Acta Haematol; 2017; 137(3):163-172. PubMed ID: 28399522
[TBL] [Abstract][Full Text] [Related]
35. Myeloma cell morphology and morphometry in correlation with clinical stages and survival.
Seili-Bekafigo I; Valković T; Babarović E; Duletić-Načinović A; Jonjić N
Diagn Cytopathol; 2013 Nov; 41(11):947-54. PubMed ID: 23554178
[TBL] [Abstract][Full Text] [Related]
36. Early Relapse for Multiple Myeloma Patients Undergoing Single Autologous Stem Cell Therapy: A Single-center Experience.
Lee H; Duggan P; Chaudhry A; Neri P; Tay J; Rashid-Kolvear F; Bahlis NJ; Jimenez-Zepeda VH
Clin Lymphoma Myeloma Leuk; 2018 Jan; 18(1):e69-e75. PubMed ID: 29158114
[TBL] [Abstract][Full Text] [Related]
37. Atypical imaging feature of non-secretory multiple myeloma.
Neeravari A; Netravati P; Mohammed R; Ragupathi AR; Nagarajappa AH
Ann Diagn Pathol; 2011 Aug; 15(4):268-72. PubMed ID: 21546295
[TBL] [Abstract][Full Text] [Related]
38. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.
Durie BGM; Hoering A; Abidi MH; Rajkumar SV; Epstein J; Kahanic SP; Thakuri M; Reu F; Reynolds CM; Sexton R; Orlowski RZ; Barlogie B; Dispenzieri A
Lancet; 2017 Feb; 389(10068):519-527. PubMed ID: 28017406
[TBL] [Abstract][Full Text] [Related]
39. Clinical characteristics and prognosis of immunoglobulin D myeloma in the novel agent era.
Chen L; Fan F; Deng J; Xu J; Xu A; Sun C; Hu Y
Ann Hematol; 2019 Apr; 98(4):963-970. PubMed ID: 30610280
[TBL] [Abstract][Full Text] [Related]
40. Non-secretary multiple myeloma in a young Ethiopian: case report.
Teklesilassie H; Sherif A; Diro E
Ethiop Med J; 2010 Apr; 48(2):165-8. PubMed ID: 20608020
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
